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Abstract: Background: Cancer-cachexia induces a variety of metabolic disorders, including skeletal muscle
imbalance. Alternative therapy, as nutritional supplementation with leucine, shows a modulatory
effect over tumour damage in vivo and in vitro. Method: Adult rats distributed into Control (C),
Walker tumour-bearing (W), control fed a leucine-rich diet (L), and tumour-bearing fed a leucine-rich
diet (WL) groups had the gastrocnemius muscle metabolomic and proteomic assays performed
in parallel to in vitro assays. Results: W group presented an affected muscle metabolomic and
proteomic profile mainly related to energy generation and carbohydrates catabolic processes,
but leucine-supplemented group (WL) recovered the energy production. In vitro assay showed
that cell proliferation, mitochondria number and oxygen consumption were higher under leucine
effect than the tumour influence. Muscle proteomics results showed that the main affected cell
component was mitochondria, leading to an impacted energy generation, including impairment in
proteins of the tricarboxylic cycle and carbohydrates catabolic processes, which were modulated and
improved by leucine treatment. Conclusion: In summary, we showed a beneficial effect of leucine
upon mitochondria, providing information about the muscle glycolytic pathways used by this amino
acid, where it can be associated with the preservation of morphometric parameters and consequent
protection against the effects of cachexia.
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1. Introduction
Cachexia is a multifactorial syndrome that occurs in patients with cancer, heart failure, rheumatoid
arthritis, obstructive pulmonary disease, and during chronic infections [1,2]. Approximately 9 million
patients globally are affected by cachexia, and it is considered an indicative risk factor for death [3,4].
This syndrome leads to severe host tissue wasting and intense body weight loss, mainly due to both
muscle mass loss and adipose tissue decrement. In the late stage of cancer, cachexia is considered to be
one of the most distressing phases, which causes not only functional impairment and psychological
anguish but also decreases the anticancer treatment responses [5]. It is important to consider multiple factors
while developing treatment options for cancer cachexia to maintain the quality of life of these patients [6].
Therefore, studies have been searching for better knowledge about the cachexia-induced molecular
alterations on metabolic processes [7,8]. These studies about the drugs, nutritional supplementation
and physical activity are working out to understand better how they could help and minimise the
cachexia state, mainly focusing the lean body mass.
Accordingly, coadjuvant treatments such as nutritional supplementation with branched-chain
amino acids could be an alternative to attenuate the effects of cachexia. More specifically, leucine
has shown some beneficial impacts on reversing the severe damage caused by cachexia, mainly by
the effective action in the maintenance of muscle protein synthesis and reducing proteolysis [7–11].
Indeed, there is an increased number of studies about nutritional supplementation in cachectic
models [12,13], especially using leucine, where the exact mechanism and molecular action in cachexia
remains unclear [14]. However, recent works show that the cachexia state affects the muscle energy
generation throughout mitochondria, and leucine supplementation could modulate this process [15].
Mitochondria is the central energy-generating organelle in eukaryotic cells, and their imbalances
cause profound changes to cells, especially to glycolytic pathway performance changing the whole
cellular function [16,17]. Recent studies have shown that mitochondria are an essential framework
for understanding the cachexia process [18], highlighting that during cancer-cachexia, there is both
an imbalance in skeletal muscle mitochondrial biogenesis [18] and an increase in mitochondrial
apoptosis [19]. Therefore, the use of an alternative nutritional scheme that supports the integrity and
activity of mitochondria may be useful to maintain the lean mass in cachectic patients.
In the last few years, studies focused on physiology and damages of muscle mitochondria during
cancer-induced cachexia [18,20,21]. Therefore, it is appropriate to investigate new evidence regarding
the mechanism by which amino acids, particularly leucine, could improve the metabolic pathways
protecting the mitochondrial function, especially in rat muscle by accessing an experimental model
of cachexia such as Walker-256 tumour. Thus, it is known that the Walker-256 tumour grows in
an exponential pattern, killing the bearing rat approximately 25 days after the tumour implantation;
then, when there was a 3% leucine supplementation, a significant interference could be observed in
cell signalling and modulation of mTOR in host tissues, especially in the gastrocnemius muscle [14].
In this way, to investigate many metabolic pathways, we used the metabolomic and proteomic analyses
to bring information about the presence of specific metabolites and proteins in muscle tissue of
tumour-bearing groups, subjected to nutritional supplementation with leucine. In the present study,
we found that leucine supplementation modulated pathways that favoured mitochondrial biogenesis in
skeletal muscle tissue and cell, maintaining the energy production activity. Therefore, the improvement
of mitochondrial function during tumour development by using a leucine-rich diet contributes to
mitochondrial enzymes and proteins related to the generation of more energy for the muscle tissue,
minimising the effects of an experimental model of cachexia.
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2. Results
2.1. Tumour-Induced Morphometric Damages Time-Course Dependent Were Modulated by Leucine-Rich Diet
Our results showed that both tumour-bearing groups (W and WL) had decreased body weight
gain along experimental time in comparison to their respective control group (Table 1). However,
the body weight gain in WL was significantly higher than in the W group (Table 1). The tumour
evolution imposed a damaging effect on muscle weights at 14th and 21st days only for the W group.
The tumour weight had no change in both groups, showing an exponential growth curve. The lean
body mass reduced in both tumour-bearing groups, but was more pronounced in W group, at 14th
and 21st days. Body fat percentage decreased in both tumour group at 21st day, associated with an
increased body water percentage in both tumour-bearing groups, describing the characteristic process
of cachexia state in this experimental model of cachexia. This process happened in a dependent
time-course (Table 1).
Table 1. Morphometric parameters of all experimental groups subjected or not to leucine-rich diet and
tumour-bearing or control groups as a time-course analyses.
Morphometric
Parameters
Group 7th Day 14th Day 21st Day
Mean ± SD Mean ± SD Mean ± SD
Body Weight Gain (g)
C 7.72 ± 0.13 14.45 ± 0.18 27.78 ± 2.78
L 7.84 ± 1.31 21.25 ± 2.78 34.10 ± 0.98
W 7.00 ± 0.72 10.11 ± 1.96 * 14.06 ± 1.92 *
WL 8.56 ± 0.67 13.67 ± 1.49 **# 22.13 ± 2.79 **#
Muscle Weight (g)
C 2.20 ± 0.20 2.20 ± 0.10 2.20 ± 0.20
L 2.38 ± 0.33 2.31 ± 0.19 2.11 ± 0.13
W 2.15 ± 0.19 1.78 ± 0.23 * 1.70 ± 0.16 *
WL 2.48 ± 0.26 # 2.04 ± 0.19 **# 2.02 ± 0.13 #
Lean Mass (%)
C n/e 23.39 ± 1.65 24.00 ± 1.41
L n/e 20.49 ± 5.00 23.00 ± 2.64
W n/e 11.92 ± 2.93 * 15.33 ± 3.56 *
WL n/e 15.28 ± 7.18 ** 19.25 ± 3.78 **
Body Fat (%)
C n/e 28.00 ± 1.56 29.70 ± 1.70
L n/e 36.63 ± 1.50 35.83 ± 2.45
W n/e 25.15 ± 3.40 * 23.75 ± 6.94 *
WL n/e 28.20 ± 3.12 ** 21.20 ± 6.27 **
Body Water (%)
C n/e 45.30 ± 2.20 43.00 ± 2.00
L n/e 39.43 ± 2.86 37.67 ± 0.33
W n/e 59.38 ± 1.58 * 56.50 ± 3.64 *
WL n/e 53.00 ± 2.88 ** 56.00 ± 3.48 **
Tumour Weight (g)
C - - -
L - - -
W 11.76 ± 1.89 22.14 ± 4.24 35.04 ± 3.49
WL 15.22 ± 2.05 24.76 ± 2.89 38.8 ± 2.23
Body weight gain corresponds to the difference of final body weight minus the previous body weight per day (g).
Absolute gastrocnemius muscle weight (g). Percentage of lean mass and body fat measured by DEXA analyses.
Percentage of total body water obtained by constant weight of dry carcass. Absolute tumour weight (g). For details
see Material and Method section. Legend: C, control group; W, Walker tumour-bearing group; L, rats fed a
leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet; n/e, not evaluated. Values are means ± standard
deviation (SD). * p < 0.05 difference against C group; ** p < 0.05 difference against L group; # p < 0.05 difference
against W group.
2.2. Tumour Growth Induced Metabolomic Profile Changes in Skeletal Muscle
Among 42 skeletal muscle metabolites that were identified (Tables S1–S3), five were altered in
rats euthanatised at 7th and 21st days of the experiment (Figure 1). Comparing both tumour-bearing
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groups with control groups, at day 7, glycerol increased in W7 in comparison to C7 group (Figure 1a)
and leucine and methionine enhanced in WL7 in comparison to C7 and W7 groups (Figure 1b,c).
At the 21st day, muscle carnosine content decreased in WL21 in comparison to C21 group (Figure 1d),
but glucose-6-phosphate increased in WL21 in comparison to L21 and W21 groups (Figure 1e) and WL21
group also had a higher methionine content in comparison to C21, L21 and W21 groups (Figure 1f).
During the tumour evolution (Table S4), seven metabolites were modified in rats euthanatised at
7th, 14th and 21st days of the experiment as a time-course dependent related with/without modulation
by leucine-rich diet (Figure 2). The muscle ADP content increased in W21 in comparison to W7 group
but did not change in WL21 group (Figure 2a). Carnosine content in muscle was unchanged in the
W group but deeply decreased in WL21 in comparison to earlier tumour growth in WL7 and WL14
groups (Figure 2b). Creatinine decreased in W21 when compared to the W14 group, and leucine-rich
diet did not influence this metabolite (Figure 2c). In W group, the muscle glycerol content decreased at
14th and 21st days of tumour evolution, but in leucine-treated groups, this decrease was observed only
in WL21 in comparison to WL7 group (Figure 2d). Leucine-rich diet influenced the muscle content,
increasing the glycine and decreasing the leucine contents in WL14 and WL21 in comparison to WL7
group (Figure 2e,f). Additionally, muscle NAD+ content increased in W and WL groups at 14th day
when compared to W7 and WL7 groups but decreased in WL21 in comparison to WL14 (Figure 2g).
2.3. Walker Factor-Induced Damages in C2C12 Myotubes Were Modulated by Leucine Treatment
In in vitro assays with C2C12 myotubes, we observed that both groups treated with WF and WFL
presented lower cell proliferation than groups C and L (Figure 3a). However, the leucine-supplemented
medium improved this process showing that the WFL group had an enhanced cell proliferation in
comparison to W group (Figure 3a). Although the Walker Factor induced lower cell proliferation,
the mitochondria activity increased in leucine-treated groups (Figure 3a), which is corroborated by
the higher proportion of mitochondria in C2C12 myotubes treated with leucine (ultrastructure images,
and graphic showed in Figure 3b–transmission electron microscopy, mitochondria numbers and area).
Oxygen consumption showed that leucine-treated C2C12 myotube presented a higher respiratory rate
(maximal mitochondrial consumption and spare respiratory capacity) even under the presence of the
Walker Factor (Figure 3c). These results indicated that leucine treatment could improve the oxygen
consumption associated with an increased ATP production in association with an increased number of
mitochondria (Figure 3b).
Among 32 myotube metabolites that were identified (Table S5), seven were altered in C2C12 cells
(Figure 4). The leucine-treated group (WFL) had an increased aspartate in comparison to the WF
group, as well as the choline content in contrast to C, L and WF groups (Figure 4a,b). Dimethylamine
and glucose-6-phosphate were increased in WFL in comparison to C and WF groups (Figure 4c,d).
Glutamine, N-Acetyllysine and sarcosine increased in WFL when compared to C, L and WF groups
(Figure 4e–g).
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Figure 1. Skeletal muscle metabolic profile identified in rats euthanatised at 7th and 21st days of the experiment. Concentration of (a) Glycerol; (b) Leucine; (c) 
Methionine; (d) Carnosine; (e) Glucose-6-phosphate; (f) Methionine metabolites in different groups. Rats were distributed into control (C7 and C21); fed a 
leucine-rich diet (L7 and L21); Walker tumour-bearing (W7 and W21) and Walker tumour-bearing fed a leucine-rich diet (WL7 and WL21) euthanatised at 7th and 
21st days of the experiment. Legend: C, control group; W, Walker tumour-bearing group; L, rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich 
diet. Data were expressed as mean ± standard deviation (SD) and analysed by one-way ANOVA followed by Tukey. (a) p < 0.05 comparison to C; (b) p < 0.05 
comparison to L and (c) p < 0.05 comparison to W. 
Figure 1. Skeletal muscle metabolic profile identified in rats euthanatised at 7th and 21st days of the experiment. Concentration of (a) Glycerol; (b) Leucine;
(c) Methionine; (d) Carnosine; (e) Glucose-6-phosphate; (f) Methionine metabolites in different groups. Rats were distributed into control (C7 and C21); fed a
leucine-rich diet (L7 and L21); Walker tumour-bearing (W7 and W21) and Walker tumour-bearing fed a leucine-rich diet (WL7 and WL21) euthanatised at 7th and 21st
days of the experiment. Legend: C, control group; W, Walker tumour-bearing group; L, rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet.
Data were expressed as mean ± standard deviation (SD) and analysed by one-way ANOVA followed by Tukey. (a) p < 0.05 comparison to C; (b) p < 0.05 comparison to
L and (c) p < 0.05 comparison to W.
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Figure 2. Skeletal muscle metabolic profile identified in rats euthanatised at 7th, 14th and 21st days of the experiment. Concentration of (a) ADP; (b) Carnosine; (c) 
Creatinine; (d) Glycerol; (e) Glycine; (f) Leucine; (g) NAD+. Rats were distributed into Walker tumour-bearing (W7, W14 and W21) and Walker tumour-bearing fed 
a leucine-rich diet (WL7, WL14 and WL21) euthanatised at 7th, 14th and 21st days of the experiment. Legend: C, control group; W, Walker tumour-bearing group; 
L, rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet. Data were expressed as mean ± standard deviation (SD) and analysed by one-way 
ANOVA followed by Tukey. (a) p < 0.05 comparison to W7; (b) p < 0.05 comparison to W14; (a’) p < 0.05 comparison to WL7 and (b’) p < 0.05 comparison to WL14. 
i r 2. Skeletal muscle metabolic profile identified in rats euthanatised at 7th, 14th and 21st days of th experime t. Conce tration of (a) ADP; (b) Carnosine;
(c) Creatinine; (d) Glycerol; (e) Glycine; (f) Leucine; (g) NAD+. Rats were dis ributed into Walker t mou -bearing ( 7, W14 and W21) and Walker tumou -bearing fed
l i -ric diet ( L7, L14 and WL21) euthanatised at 7th, 14th and 21st days of th experiment. L gend: C, control group; , Walker tumour-bearing group; L,
rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet. Data were xpressed as mean ± standar deviation (SD) and analysed by one-way ANOVA
followed by Tukey. (a) p < 0.05 comparison to W7; (b) p < 0.05 comparison to W14; (a’) p < 0.05 comparison t WL7 and (b’) p < 0.05 comparison to WL14.
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Figure 3. C2C12 myotubes parameters under Walker Factor effects and modulation by leucine treatment. (a) In vitro MTT assay for assessing cell mitochondrial 
activity in C2C12 myotubes subjected to Walker Factor and leucine supplementation. (b) Representative ultrastructure images of mitochondria from C2C12 
myotubes. Groups without tumour presented a greater number of mitochondria, when compared to the other tumour-bearing groups (W and WL). The leucine 
supplemented tumour-bearing group (WL) had more mitochondria than the tumour-bearing group fed a control diet (W). Magnification 10000×. Scale bar: 2µm, 
arrows indicate mitochondria. Bar graphics show the mitochondrial number and area for each group. (c) Basal O2 mitochondrial consumption; maximal 
mitochondrial respiration and spare respiratory capacity of the C2C12 myotubes measured in Oroboros Oxygraph-2K and DatLab software package (OROBOROS, 
Innsbruck, Austria). Experimental design applied on myotubes cells were sequentially treated with Oligomycin A (1 µM), FCCP (0.5 µM), and Antimycin A (1 µM) 
as indicated by the arrows. For more details see Material and Methods section. Leucine-treated C2C12 myotubes were incubated with leucine (50 µM, Sigma) for 24 
h. Tumour-treated C2C12 myotubes were incubated for 24 h with Walker Factor at final concentrations of 25 µg/mL. Leucine/Walker Factor-treated C2C12 myotubes 
were exposed to 50 µM leucine and supplemented with tumour Factor at final concentrations of 25 µg/mL. For more details see Material and Methods section. 
Legend: control (C); leucine supplementation medium (L); Walker Factor treatment (WF) and Walker Factor treatment and leucine supplementation medium 
(WFL). * p < 0.05 difference against C group; ** p < 0.05 difference against L group: # p < 0.05 difference against WF group.
Figure 3. C2C12 myotubes parameters under Walker Factor effects and odulation by leucine treatment. (a) In vitro MTT assay for assessing cell mitochondrial
activity in C2C12 myotubes subjected to Walker Factor and leucine supplementation. (b) Representative ultrastructure images of mitochondria from C2C12 myotubes.
Groups without tumour presented a greater number of mitochondria, when compared to the other tumour-bearing groups (W and WL). The leucine supplemented
tumour-bearing group (WL) had more mitochondria than the tumour-bearing group fed a control diet (W). Magnification 10000×. Scale bar: 2µm, arrows indicate
mitochondria. Bar graphics show the mitochondrial number and area for each group. (c) Basal O2 mitochondrial consumption; maximal mitochondrial respiration and
spare respiratory capacity of the C2C12 myotubes measured in Oroboros Oxygraph-2K and DatLab software package (OROBOROS, Innsbruck, Austria). Experimental
design applied on myotubes cells were sequentially treated with Oligomycin A (1 µM), FCCP (0.5 µM), and Antimycin A (1 µM) as indicated by the arrows. For more
details see Material and Methods section. Leucine-treated C2C12 myotubes were incubated with leucine (50 µM, Sigma) for 24 h. Tumour-treated C2C12 myotubes
were incubated for 24 h with Walker Factor at final concentrations of 25 µg/mL. Leucine/Walker Factor-treated C2C12 myotubes were exposed to 50 µM leucine and
supplemented with tumour Factor at final concentrations of 25 µg/mL. For more details see Material and Methods section. Legend: control (C); leucine supplementation
medium (L); Walker Factor treatment (WF) and Walker Factor treatment and leucine supplementation medium (WFL). * p < 0.05 difference against C group; ** p < 0.05
difference against L group: # p < 0.05 difference against WF group.
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Figure 4. C2C12 Myotube metabolic profile identified in C2C12 cells. Concentration of (a) Aspartate; (b) Choline; (c) Dimethylamine; (d) Glucose-6-phosphate; (e) 
Glutamine; (f) N-Acetyllysine; (g) Sarcosine. C2C12 myotube cells were distributed into control (C); leucine supplementation medium (L); Walker Factor treatment 
(WF) and Walker Factor treatment and leucine supplementation medium (WFL). Data were expressed as mean ± standard deviation (SD) and analysed by one-way 
ANOVA followed by Tukey. (a) p < 0.05 comparison to C; (b) p < 0.05 comparison to L and (c) p < 0.05 comparison to W. 
Figure 4. C2C yotube metabolic profile identified in C2C12 cells. Concentration of (a) Aspartate; (b) Choline; (c) Dimethylamine; (d) Glucose-6-phosphate;
(e) Glutamine; (f) N-Acetyllysine; (g) Sarcosine. C2C12 myotube cells were distributed into control (C); leucine supplementation medium (L); Walker Factor treatment
(WF) and Walker Factor treatment and leucine supple entation ediu ( FL). ata ere expressed as mean ± standard deviation (SD) and analysed by one-way
ANOVA followed by Tukey. (a) p < 0.05 co parison to C; (b) p < 0.05 comparison to L and (c) p < 0.05 comparison to W.
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2.4. Muscle Proteomic Profile Changed by Tumour Evolution but Was Diverted by Leucine-Rich Diet
Through proteomic analysis, we could compare the muscles of tumour-bearing rats without
(W) and with leucine nutritional supplementation (WL), and realised that the presence of this amino
acid in the diet altered mitochondrial proteins (34 different proteins in higher content in WL muscle
than in W group, and three more mitochondrial proteins in lower content in WL about W group
(Table 2). Additionally, in Table 3, the proteomic analysis could find changes in processes like
molecular functions, biological processes and also the cellular components, when the comparison
was made between both tumour-bearing groups, showing that the nutritional supplementation
improved this functional component of the muscle cells. To display the different concentration of the
identified proteins, we chose to compare the groups using the fold change values of each protein,
always comparing one by one. We observed a significant increase in the concentration of enzymes
that participate in processes for energy generation, such as malate dehydrogenase—Mdh1 (P93819)
and Mdh2 (P04636) (Figure 5a,b, respectively; Table 2) among the leucine-treated groups. These two
portions presented high concentrations influenced by leucine supplementation, in WL and L groups,
when compared to the non-supplemented groups, showing that the nutritional supplementation could
affect some point of the tricarboxylic acid cycle in these cachectic muscles. Glycogen-phosphorylase,
Pygm (P09812) showed higher concentrations in both tumour-bearing groups, being more pronounced
in the W group compared to the C, but less intense in the WL group compared to the L (Figure 5c;
Table 2). Protein pyruvate dehydrogenase beta, Pdhb (P49432) appeared in higher concentrations in
leucine-treated groups, besides the WL group had an increased content compared to the W group
(Figure 5d; Table 2). Phosphoglucomutase-1, PGm1 (P38652; Table 2) had higher concentrations again
in both leucine groups with or without tumour implant than the C and W groups (Figure 5e).
The present results showed throughout the proteomic analysis in muscle samples that the presence
of the family of ATP synthases was in higher concentrations in the WL group compared to the W group
(Table 2; Figure 6a). Since these proteins were deeply reduced in W group when compared to C group
and slightly reduced in WL in comparison to L, we chose to present the graphic differences only between
WL vs. W (see the differences in Tables S6–S10). This proteins family belongs to the mitochondrial
membrane and acts on the synthesis of ATP from ADP in the presence of a proton gradient across the
membrane, which is generated by the electron transport complexes of the respiratory chain. Under the
nutritional leucine supplementation, there was some modulation of this muscle ATP family, as presented
in Figure 6a. Herewith, we observed changes in expression of flavoprotein (FP) subunit of succinate
dehydrogenase (SDHa; Q920L2; Figure 6b) with higher values under leucine-rich diet, showing the
modulatory effect, especially in tumour-bearing groups (Figure 6b). There was no significant difference
between group W and C; C and L (see the results in Tables S6–S10). Under leucine supplementation,
the WL group presented the enzyme Creatine kinase M-type, Ckm (P00564) Ckm down-regulated
in comparison to W (Figure 6b). On the other hand, creatine kinase S-type, Ckmt2 (P09605; Table 2,
Figure 6b) had a higher concentration in WL compared to W group. Beta-enolase, Eno3 (P15429;
P07323) was higher in WL group than the W group (Figure 6b).
Confirming the results obtained in proteomic analysis, the protein expression of some enzymes
related to the mitochondria function was analysed by Western blotting. Cytochrome C oxidase
(OXPHOS—Complex IV) shows a decreased expression in the W group when compared to the WL
group, and against to the other control groups (Figure 6c), indicating changes in the accomplishment
of oxidative phosphorylation and consequent reduction in energy production. Supporting this issue,
the cyclic AMP responsive element-binding protein—Creb protein—involved with pathways between
impaired mitochondria and the nucleus presented higher values in W compared to WL, indicating
significant mitochondrial dysfunction (Figure 6c), being compatible with the higher muscle wasting
presented in this group. Moreover, the WL group showed a lower tumour-induced muscle wasting
which reinforced the benefits of leucine recovering the mitochondrial function.
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O88989 and (b) malate dehydrogenase mitochondrial—Mdh2, accession code P04636 in 
gastrocnemius muscle under effects of Walker-tumour development and nutritional 
supplementation with leucine. (c) Glycogen phosphorylase—Pygm, accession code P09812 and (d) 
Pyruvate dehydrogenase E1 component—Pdhb, accession code P49432 in gastrocnemius muscle. (e) 
Phosphoglucomutase-1—Pgm1, accession code P38652 in gastrocnemius muscle. The values are 
expressed as the difference of maximal fold change. Legend: C, control group; W, Walker 
tumour-bearing group; L, rats fed a leucine-rich diet; WL, tumour-bearing rats fed a leucine-rich diet. 
* p < 0.05 difference against C group; ** p < 0.05 difference against L group: # p < 0.05 difference 
against WF group. 
Figure 5. Muscle proteomic profile in all experimental groups subject or not to leucine-rich diet and bearing or not Walker-256 tumour. (a) malate dehydrogenase
cytoplasmic—Mdh1, accession code O88989 and (b) malate dehydrogenase mitochondrial—Mdh2, accession code P04636 in gastrocnemius muscle under effects
of Walker-tumour development and nutritional supplementation with leucine. (c) Glycogen phosphorylase—Pygm, accession code P09812 and (d) Pyruvate
dehydrogenase E1 component—Pdhb, accession code P49432 i gastro n mius muscle. (e) Phosphoglucomutase-1—Pgm1, accession code P38652 in gastrocnemius
muscle. The values are expressed as the difference of maximal fold change. Legend: C, control group; W, Walker tumour-bearing group; L, rats fed a leucine-rich diet;
WL, tumour-bearing rats fed a leucine-rich diet. * p < 0.05 difference against C group; ** p < 0.05 difference against L group: # p < 0.05 difference against WF group.
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Figure 6. Muscle mitochondrial proteins of all experimental groups subject or not to leucine-rich diet 
and bearing or not Walker-256 tumour. (a) ATP Synthases family: average concentrations of the ATP 
synthase complex subunit B1 (accession code P19511), subunit alpha (accession code P15999), 
subunit beta (accession code P10719), subunit d (accession code P31399), subunit e (accession code 
P29419), subunit gamma (accession code P35435) and subunit O (accession code Q06647). (b) 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit—Sdha (accession code Q920L2); 
Creatine Kinase M-type, cytoplasmic—Ckm (accession code P00564); Creatine Kinase S-Type, 
mitochondrial—Ckmt2 (accession code P09605/P25809); Beta-Enolase—Eno3 (accession code 
P15429/P07323). (c) OXPHOS proteins of Western blot assay: Protein CREB phosphorylated (p-Creb: 
43 kDa; loading control vinculin 124 kDa), OXPHOS—Complex IV (40 kDa; loading control tubulin 
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Figure 6. Muscle mitochondrial proteins of all experi ental groups subject or not to leucine-rich diet and bearing or not Walker-256 tumour. (a) ATP Synthases family:
average concentrations of the ATP synthase complex subunit B1 (accession code P19511), subunit alpha (accession code P15999), subunit beta (accession code P10719),
subunit d (accession code P31399), subunit e (accession code P29419), subunit gamma (accession code P35435) and subunit O (accession code Q06647). (b) Succinate
dehydrogenase [ubiquinone] flavoprotein subunit—Sdha (accession code Q920L2); Creatine Kinase M-type, cytoplasmic—Ckm (accession code P00564); Creatine
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Cancers 2020, 12, 1880 12 of 25
Table 2. The highest and lowest mitochondrial proteins concentration identified in rats with Walker tumour-bearing fed/not fed a leucine-rich diet and euthanatised at
21st day of the experiment.
Accession Description Max Fold Change Highest Mean Condition Lowest Mean Condition
Q5XI78 2-oxoglutarate dehydrogenase, mitochondrial GN = Ogdh 1.805 WL W
17764 Acetyl-CoA acetyltransferase, mitochondrial GN = Acat1 >5 WL W
Q9ER34 Aconitate hydratase, mitochondria GN = Aco2 1.811 WL W
P00507 Aspartate aminotransferase, mitochondrial GN = Got2 1.196 WL W
P19511 ATP synthase F(0) complex subunit B1, mitochondrial GN = Atp5f1 >5 WL W
P10719 ATP synthase subunit beta, mitochondrial GN = Atp5b 4.378 WL W
P31399 ATP synthase subunit d, mitochondrial GN = Atp5h 3.048 WL W
P29419 ATP synthase subunit e, mitochondrial GN = Atp5i 1.477 WL W
P35435 ATP synthase subunit gamma, mitochondrial GN = Atp5c1 4.358 WL W
Q06647 ATP synthase subunit O, mitochondrial GN = Atp5o 1.420 WL W
Q8VHF5 Citrate synthase, mitochondrial GN = Cs 3.133 WL W
P09605; P25809 Creatine kinase S-type, mitochondrial GN = Ckmt2 4.191 WL W
P32551 Cytochrome b-c1 complex subunit 2, mitochondrial GN = Uqcrc2 1.853 WL W
P10888 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial GN = Cox4i1 3.775 WL W
P11240 Cytochrome c oxidase subunit 5A, mitochondrial GN = Cox5a 2.577 WL W
P12075 Cytochrome c oxidase subunit 5B, mitochondrial GN = Cox5b >5 WL W
P13803 Electron transfer flavoprotein subunit alpha, mitochondrial GN = Etfa 1.343 WL W
P14408 Fumarate hydratase, mitochondrial GN = Fh >5 WL W
P10860 Glutamate dehydrogenase 1, mitochondrial GN = Glud1 2.046 WL W
P56574 Isocitrate dehydrogenase [NADP], mitochondrial GN = Idh2 2.443 WL W
P15650 Long-chain specific acyl-CoA dehydrogenase, mitochondrial GN = Acadl 1.182 WL W
P04636 Malate dehydrogenase, mitochondrial GN = Mdh2 1.922 WL W
P08503 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial GN = Acadm >5 WL W
Q66HF1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial GN = Ndufs1 >5 WL W
Q9R063 Peroxiredoxin-5, mitochondrial GN = Prdx5 >5 WL W
P49432 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial GN = Pdhb >5 WL W
P15651 Short-chain specific acyl-CoA dehydrogenase, mitochondrial GN = Acads 1.174 WL W
P48721 Stress-70 protein, mitochondrial GN = Hspa9 >5 WL W
Q920L2 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial GN = Sdha 3.386 WL W
B2GV06 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial GN = Oxct1 1.576 WL W
Q9Z0V6 Thioredoxin-dependent peroxide reductase, mitochondrial GN = Prdx3 1.458 WL W
Q64428 Trifunctional enzyme subunit alpha, mitochondrial GN = Hadha 1.682 WL W
Q60587 Trifunctional enzyme subunit beta, mitochondrial GN = Hadhb 2.138 WL W
P45953 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial GN = Acadvl 3.580 WL W
Q99NA5 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial GN = Idh3a 2.031 W WL
P15999 ATP synthase subunit alpha, mitochondrial GN = Atp5a1 1.473 W WL
P13437 3-ketoacyl-CoA thiolase, mitochondrial GN = Acaa2 2.441 W WL
Rats were distributed into Walker tumour-bearing (W) and Walker tumour-bearing fed a leucine-rich diet (WL) euthanatised at 21st day of the experiment. Statistical analysis described in
Methods, showing the significant value for p < 0.05.
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Table 3. The most impacted molecular function, biological processes and cellular components in muscle
proteomic analyses identified in rats with Walker tumour-bearing fed/not fed a leucine-rich diet and
euthanatised at 21st day of the experiment.
# Pathway ID Molecular Function Pathway Description Gene Count FDR
GO.0003824 Catalytic activity 35 1.79 × 10−19
GO.0016491 Oxidoreductase activity 17 2.23 × 10−14
GO.0015078 Hydrogen ion transmembrane transporter activity 10 1.50 × 10−13
GO.0043167 Ion binding 29 1.33 × 10−12
GO.0048037 Cofactor binding 11 1.09 × 10−10
GO.0009055 Electron carrier activity 7 1.71 × 10−09
GO.0050662 Coenzyme binding 9 6.65 × 10−09
GO.0003674 Molecular function 33 1.48 × 10−08
GO.0046872 Metal ion binding 20 1.48 × 10−08
GO.0005215 Transporter activity 14 2.68 × 10−08
# Pathway ID Biological Process Pathway Description Gene Count FDR
GO.0006091 Generation of precursor metabolites and energy 20 6.99 × 10−29
GO.0044710 Single-organism metabolic process 34 3.18 × 10−23
GO.0055114 Oxidation-reduction process 24 3.18 × 10−23
GO.0019752 Carboxylic acid metabolic process 21 1.59 × 10−19
GO.0072350 Tricarboxylic acid metabolic process 10 1.54 × 10−17
GO.0044281 Small molecule metabolic process 23 2.07 × 10−17
GO.0006099 Tricarboxylic acid cycle 9 3.87 × 10−16
GO.0045333 Cellular respiration 11 8.45 × 10−16
GO.0046496 Nicotinamide nucleotide metabolic process 11 8.45 × 10−16
GO.0015980 Energy derivation by oxidation of organic compounds 12 1.31 × 10−15
GO.0006732 Coenzyme metabolic process 13 2.82 × 10−15
# Pathway ID Cellular Component Pathway Description Gene Count FDR
GO.0005739 Mitochondrion 32 3.66 × 10−31
GO.0031966 Mitochondrial membrane 23 1.17 × 10−26
GO.0005740 Mitochondrial envelope 23 3.64 × 10−26
GO.0044444 Cytoplasmic part 42 1.17 × 10−25
GO.0005743 Mitochondrial inner membrane 19 1.29 × 10−23
GO.0044429 Mitochondrial part 22 1.00 × 10−22
GO.0043209 Myelin sheath 14 2.79 × 10−19
GO.0005737 Cytoplasm 39 1.46 × 10−16
GO.0043234 Protein complex 26 5.62 × 10−15
GO.0070062 Extracellular exosome 20 6.93 × 10−15
GO.0031090 Organelle membrane 24 1.04 × 10−14
GO.0031988 Membrane-bounded vesicle 22 9.29 × 10−14
False discovery rate (FDR). Statistical analysis described in Methods, showing the significant value for p < 0.05.
3. Discussion
Cancer-induced cachexia is a complex systemic disease which is characterised by higher progressive
weight loss and spoliation specifically of skeletal muscle which is reflected by intense and severe
metabolic change crosstalking to other host tissues [22]. Cachexia is still a bad condition of these cancer
patients, which depending on the stage, is rarely fully reversed [22,23]. Coadjuvant treatments are
increasing to find a way to minimise the muscle atrophy related to cachexia [17]. In the present study,
we found that leucine supplementation modulated pathways that favoured mitochondrial biogenesis
in skeletal muscle tissue and cell, maintaining the energy production activity. In a cachectic state,
this process showed a beneficial effect, minimising the deleterious effects of lean mass loss induced by
tumour growth evolution, as presented here by the Walker tumour-induced muscle wasting. As seen
here, the body weight gain, muscle weight and lean body mass were preserved in tumour-bearing
animals which received leucine supplementation (WL) counteracting the highly wasting imposed by
tumour-induced damages as observed in W group as a time-dependent way, starting on 14th day after
tumour implant. This data corroborated with the literature, which shows that the tumour evolution
is directly related to the spoliation of adipose tissue and decrease in muscle mass [13]. Another
specific point related to cachexia state is oedema found in cancer patients and also in experimental
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animals [24]. Consistent with this fact, using the experimental model of cachexia—Walker-256
tumour—we observed deeply decrease in body fat and lean body mass was associated with higher
body water content in both tumour-bearing independently of the nutritional scheme. As presented,
we did not find any statistical differences in tumour weight evolution between both experimental
groups. Despite having no increase in tumour mass, leucine supplementation stimulated the mTOR
expression in Walker-256 tumours tissue, without additional growth [25]. As reported by Nakano
and colleagues, leucine and other branched-chain amino acids increased cell senescence induced
by DNA damage mediated by the mTORC1 pathway to regulate p21 translation [26], which could
potentially explain the lack of increased proliferation in response to leucine supplementation. Moreover,
considering the great importance in elucidating the effects of leucine supplementation in tumour
growth, Viana and colleagues showed that the leucine diet led to a tumour metabolic shifting from
glycolytic towards oxidative phosphorylation, reducing glucose consumption and metastasis formation,
suggesting that the leucine nutritional supplementation had no benefit to the same experimental
tumour model, as worked here [27]. Meanwhile, despite not increasing the tumour mass, leucine
nutritional supplementation had also no benefit to this type of tumour, and as far as we know, clinical
studies focused on leucine supplementation in cancerous tissues in patients are lacking, showing the
limitations of an experimental model being translated to patients.
The morphometric alterations were accompanied by metabolic changes in the skeletal muscle
tissue from both tumour-bearing groups. Both tumour-bearing groups exhibited alterations in some
specific metabolites related to energy production, protein, and amino acid metabolism. Therefore,
these metabolic alterations were mainly related to cachexia-induced muscle atrophy, as verified in vivo
and in vitro assays [28]. These metabolic pathways may be involved in the high activity of skeletal
muscle tissue [29]. Besides, the altered metabolites played a role in amino acid synthesis by reflecting the
proteolysis occurred in skeletal muscle affected by the tumour growth effects, as tumour factors (Walker
factor) and also in the whole host by the higher pro-inflammatory cytokines, as previously found [14].
For some of the omics experiments, there were limitations associated with a reduced sample
number per group, therefore for some specific metabolites there was no significant differences. Higher
levels of 3-methylhistidine, a product of peptide bond synthesis and the methylation of actin and
myosin, were detected in both tumour-bearing groups later in the tumour progression. In this way,
we chose to analyse the percentage of the content against the control group, and we verified that
the W group started with higher muscle 3-methylhistidine at day 7 (4.4-fold; p = 0.0365) and this
increased content remained on 14th (3.6-fold) and 21st days (2.9-fold), without showing significance
(p = 0.2680 and p = 0.3380, respectively). On the other hand, the leucine-treated groups showed
enhanced 3-methylhistidine content in muscle, independently of bearing a tumour or not (WL vs. L
had 0.8-fold; 1.5-fold and 2.3-fold on 7th, 14th and 21st day, without showing statistical significance;
p = 0.6763; p = 0.4713; and p = 0.9811, respectively). The increase in 3-methylhistidine provides an
index for the rate of muscle protein breakdown [30–32]. Researchers have previously shown a positive
correlation between increased 3-methylhistidine and cancer progression, along the cancer cachexia,
due to the high muscle protein breakdown [32]. At present work, the W group started to increase
3-methylhistidine at 7th day, whereas in the leucine-treated rats had no difference. This point could be
related to a prediction of cachexia starting and the leucine effects modulating the tumour-induced
muscle protein breakdown and collaborating to the maintenance of host carcass.
Another point to discuss over the metabolomic results is that the reduction in muscle carnosine
may be associated with a possible targeting of this metabolite to the tumour, since recent research
pointed the potential physiological effects of carnosine exerts in all host tissues, and also in cancer
cells [33,34]. Carnosine was related to the ability to inhibit glycolysis in tumour cells, by its carbonyl
quenching ability and therefore reducing the generation of ATP [35,36]. In an exploratory view,
we observed a slightly reduction of muscle carnosine in W21 group, and an expressive reduction
in WL21 group. Despite this profound significance, showing that leucine potentiated the carnosine
reduction, it could not be sustained as an anti-neoplastic action, because there is no difference in tumour
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mass in experimental groups. Most carnosine that reach the bloodstream is immediately hydrolysed
into beta-alanine and histidine [36]. For this reason, carnosine was unable to reach the tumour and
perform its antiproliferative role, thus further studies on muscle and tumour are needed to better
understand the role of carnosine.
To mimic, in vitro, the effects of cachexia, observed in skeletal muscle tissue from Walker 256
tumour-bearing rats, we treated C2C12 myotubes with Walker Factor (WF) to evaluate the modulatory
impact of leucine when muscle cells were exposed to WF. The WF, isolated from the ascitic fluid
removed from a cachectic Walker 256 tumour-bearing rat [37], acts as the proteolysis-induced factor [38].
In the present study, we verified the proliferation of C2C12 cells exposed to WF and treated with leucine
(WFL group) compared to the non-treated group (WF). This fact indicated that the presence of leucine
stimulated mitoses [39,40], probably because there was a maintenance of the machinery responsible
for energy production, keeping a physiological mitochondrial activity [17,41]. The maintenance of
the mitochondrial activity and consequent oxidative phosphorylation (OXPHOS) metabolism were
also observed in oxygen consumption rate, number and area of mitochondria in leucine-treated
groups, even exposed the Walker Factor [42,43]. This fact indicated that mitochondrial function was
likely preserved in WFL, showing the beneficial effect of leucine, which could be extended to the
leucine-treated tumour-bearing animals. Corroborating the present results, our proteomic data showed
that the muscle mitochondrial enzymes involved in the generation of energy through the tricarboxylic
acid cycle (TCA) were in higher concentration as shown in the groups supplemented with leucine,
especially in tumour-bearing group WL group when compared to the W group.
Moreover, our proteomic data showed that the W group had higher concentrations of proteins
related to glycogen mobilisation and also stimulation of glycolysis. Therefore the higher Pygm
found in W group likely was related to increased muscle glycogenolysis providing glucose for
immediate use in glycolysis reactions. In contrast, the WL group could preserve the muscle glycogen
(as previously showed [42,44] which could be in accordance with the maintenance of muscle energy
source and consequently the muscle mass. Besides that, the Mdh1 and Mdh2 proteins that are related
to mitochondrial catalytic activity and, together with the Pdhb protein, responsible for the conversion
of pyruvate to Acetyl-CoA, showed high concentration in both groups supplemented with leucine,
including the tumour-bearing group (L, WL). This fact indicated that the presence of this amino acid
stimulated the production of energy through oxidative phosphorylation (OXPHOS) process.
In line with these results, our protein expression by Western blotting also revealed that the
expression of mitochondrial proteins related to the OXPHOS complex was preserved in the leucine
group. The oxidative phosphorylation electron transport chain complex is composed of five large
protein complexes, Complex I—Complex V [43,45]. Indeed, the complexes I, III and IV are essential
components of proton pump to maintain the electrochemical transmembrane potential which generates
energy during oxidative phosphorylation; therefore, the expression of the complex IV that helped to
produce ATP [46] was reduced in tumour-bearing animals (W) but remained unchanged in the WL
group. Despite having no differences in muscle ATP content, as presented in metabolomic data, the W
tumour-bearing group showed an increased muscle ADP content, which likely suggested a higher
dissipation of energy, which did not happen in WL group. This result indicated that mitochondrial
functional activity was preserved in the WL group. On the other hand, the W group showed a reduced
concentration of mitochondrial proteins compared to the WL group. As verified by Arnould and
colleagues, the mitochondrial activity impairment is sufficient to trigger CREB phosphorylation as seen
in proliferation cells [47]. Although we were analysing muscle cells, the CREB activation suggested
the fail in energy production in these cells. Besides, we found an increase in the phosphorylated
CREB protein levels, indicating mitochondrial dysfunction or decreasing mitochondrial biogenesis
in the W group. Moreover, once leucine supplementation altered the P-CREB activation in the WL
group, we suggested that this amino acid could preserve the muscle energy production, indicating the
protection of the mitochondrial machinery.
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For this reason, the muscle tissue of tumour-bearing rats without leucine supplementation (W)
needed to mobilise energetic molecules from other sources, such as muscle glycogen store and muscular
glycolysis stimulation, as previously demonstrated by our group [48]. Additionally, the leucine group
(WL) preserved these energy sources, and probably changed this glycolytic metabolism to better gain
energy to muscle tissue supply.
ATP synthases complex is present in the mitochondrial inner membrane and acts on the synthesis
of ATP from ADP in the presence of a proton gradient across the membrane, which is generated by
the electron transport complexes of the respiratory chain. The proteins of this complex are essential
in maintaining the correct mitochondrial energy production. The higher concentration of the found
proteins (Table 2) found in the WL muscle tissue, as well the increase in maximal oxygen consumption
and spare capacity in cultured myotubes, likely indicated that the respiratory chain activity was
reestablished with the presence of leucine (Figure 7).
Other proteins involved in the mitochondrial catalytic activity, such as Pgm1, Sdha, Ckm/Ckmt2
and Eno3, also contribute to the understanding the mitochondrial activity, which was likely restored
under leucine effects. Among them, the flavoprotein subunit of succinate dehydrogenase (Sdha),
as the parting of the tricarboxylic acid cycle, was involved in complex II of the mitochondrial electron
transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme
Q). In line with our results, as seen by in vitro assay, leucine improved the maximal mitochondrial
consumption and spare respiratory capacity, suggesting a more useful ability of energy generation in
the WL muscle tissue than in W group. Besides, the higher concentration of Ckm protein in the W
group suggested a current energy generation. However, as a counteracting effect of leucine, the higher
Ckmt2 content found in the WL group likely indicated the restored mitochondrial activity to provide
muscle energy. In parallel, Eno3 is an isoenzyme found in skeletal muscle cells, which plays a role in
muscle development and regeneration [49] and also is related to catabolic glycolytic pathway. A switch
from alpha enolase to beta enolase occurs in muscle tissue during development in rodents and also
assures the mitochondria activity [50]. Corroborating with our results, the higher Eno3 concentration
found in WL suggested the activation of energy production by preserving the mitochondria activity
process more expressive than in W group.
Previously, we demonstrated that leucine supplementation increased the mTOR signalling,
which was reflected in the maintenance of the total muscle protein net [51] (Figure 7). Moreover,
a leucine-rich diet modulated pro- and anti-cachectic cytokines and the key proteins involved in the
ubiquitin-proteasome pathway in gastrocnemius muscle tissue [14]. In tumour-bearing group fed
a leucine-rich diet (the WL group) the maximum value of the cytokines was achieved at an earlier time
point (on the 14th day) than in the W group. In parallel, this parameter was associated with an earlier
increase in anti-inflammatory cytokines (IL-4 and IL-10), which could also have contributed to an
earlier induction of the anti-inflammatory process, likely protecting the host against tumour-induced
negative effects, thereby minimising the cachectic state.
This previously published work long with the new data presented here shows a relationship
(Figure 7), because the increase in energy activity through mitochondrial proteins contributed to a better
metabolic state and, consequently, stimulated processes of protection to the organism. Thus, leucine
supplementation led to improvement and anticipated the anti-inflammatory responses, ameliorating
the muscle protein synthesis and minimising the wasting. Since, we observed a modulatory effect
over the ubiquitin-proteasome pathway [14], the increased expression in proteasome catalytic subunits
likely indicated that the proteolytic process was activated in gastrocnemius muscle tissue in both
tumour-bearing groups, but this activation was slightly less intense in the WL group. For this reason,
we found in the present work that the action of ATP-synthase complex proteins is of a greater quantity
in the leucine supplemented group, which improved the muscle energy production, together with the
stimulation of protein synthesis signalling (increased mTOR signalling), resulting in an improvement
of total muscle protein balance.
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Summing up, these results contribute to better understand the beneficial effects of leucine for
the cachectic host organism, especially to the skeletal muscle metabolism. Therefore, further studies
are now ongoing in our laboratory to improve the understanding of the leucine effects in the skeletal
muscle from cachectic hosts. The present work presented information that serves as a basis for new
developments in this field of study. It is well established that in the cachexia state there is a significant
decrease in the expression of genes involved in mitochondrial fusion, fission, ATP production and also
mitochondrial density [15], leading to an impaired mitochondrial function.
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Figure 7. Illustration summarising the main processes found in both experimental groups. Legend: W,
Walker tumour-bearing group, represented in blue; and WL, tumour-bearing rats fed a leucine-rich
diet, represented in green colour. Arrows directions show the variation of the events between
both groups. Glycogen phosphorylase (Pygm) is involved in muscle glycogenolysis and glycolysis.
Phosphoglucomutase-1 (Pgm1) has a catalytic activity breakdown and synthesis of glucose. Pyruvate
dehydrogenase E1 component (Pdhb) plays a role in the process of converting pyruvate to Acetyl-CoA.
ATP synthases complex is for the production of ATP by the respiratory chain, mitochondrial function.
Muscle protein synthesis and signalling events were published previously by Cruz and colleagues [51].
4. Materials and Methods
4.1. In Vivo Assays
4.1.1. Diets
The semi-purified isocaloric diets were in accordance to American Institute of Nutrition as a
normal-protein diet (C), containing 18% protein, and leucine-rich diet (L), including 18% protein
plus 3% L-leucine [52]. Both diets contained approximately 60% carbohydrate (sucrose, dextrin and
starch), 7% fat (soybean oil) and 5% fibre (purified micro-cellulose). Vitamins and mineral mix, as well
as cystine and choline, supplemented the diets. The control diet contained 1.6% L-leucine, and the
leucine-rich diet contained 4.6% L-leucine, according to the protein source from casein, as used in
Cancers 2020, 12, 1880 18 of 25
our previous experimental studies [11]. Prior to these experiments dose-response assays were carried
out with 1.5, 3.0, 4.5 and 6% leucine as a supplementation to the control diet, and all positive effects
were found with 3% leucine supplementation shown in all morphometric and biochemical parameters
including skeletal muscle [14,51]. Above 4.5% of leucine had no additional increase in positive effects.
Animals with cachexia, for both groups W and WL, had anorexia causing them to obtain a lesser
diet than healthy animals. We conducted previous studies, with pair-fed groups, where we supplied
the same amount of diet ingested by the groups with tumour to the other non-tumour-bearing groups,
that is, the weight of the diet provided was normalised by the weight of the ingestion of the tumour
group. Therefore, we have already validated in our laboratory that the amount of food ingested did
not interfere with the parameters analysed in our experiments [14,51].
4.1.2. Animal and Experimental Procedures
Male Wistar rats (n = 72 animals; 90-days-old, weighing 350–380 g) were obtained from the
Centre/UNICAMP animal facilities (CEMIB/State University of Campinas, Brazil), and received food and
water ad libitum under light-dark cycles (12/12 hours each) and constant temperature (22 ± 2 ◦C) and
humidity (50–60%). The animals were distributed into 4 groups based on tumour implant (1× 106 viable
cells of Walker-256 tumour injected in the right subcutaneous flank; cell viability obtained by trypan
blue exclusion) and subjected or not to leucine-rich diet following the groups: 1. Control (C) subjected
to a normoproteic diet; 2. Leucine (L) subjected to leucine-rich diet; 3. Tumour-bearing (W) subjected to
a normoproteic diet, and implanted with Walker 256 carcinosarcoma cells; 4. Leucine tumour-bearing
(WL) subjected to leucine-rich diet and implanted with Walker 256 carcinosarcoma cells. Each group
contained a minimum of four animals for the metabolomic assay, and a minimum of six for the other
analyses. The general UKCCCR [53] guidelines for animal welfare were followed, and the Institutional
Committee for Ethics in Animal Research approved the study protocol (CEEA/IB/UNICAMP, protocol
number #4918-1).
All animals remained in collective cages, and the body weight and tumour evolution were analysed
every three days. After the 7th, 14th or 21st days of the experiment, all animals were randomised
and euthanised on each day by decapitation. After euthanasia, to evaluate and establish trends
regarding changes in metabolomics profiles in muscles and the effects of these changes in mitochondria,
the gastrocnemius muscle and tumour was quickly dissected, weighed, frozen in liquid nitrogen and
subsequently stored in −80 ◦C for further biochemical and molecular analyses. The metabolomics
assays were accessed on 7th, 14th and 21st days. In our experimental conditions and also as an
expensive assay, we chose to perform the proteomics assays only at day 21 as the results were more
significant under the tumour effects and also leucine modulation.
4.2. In Vitro Assays
C2C12 myoblast cells from Cancer Research Laboratory (Aston University, Birmingham, UK)
were grown in DMEM-high glucose medium (Sigma Chemical Company, St. Louis, MO, USA)
supplemented with 10% foetal calf serum (FCS, Sigma) and 1% penicillin/streptomycin (P/S, Sigma) at
37 ◦C in a humidified 5% CO2 atmosphere. The myoblast cells, at 80% confluence, were differentiated
into myotubes, using the propagation medium replaced by medium supplemented with 2% horse
serum. Cells were assayed experimentally within 5 days of differentiation. Leucine-treated C2C12
myotubes were incubated with leucine (50 µM, Sigma) for 24 h [54]. Walker Factor-treated C2C12
myotubes were incubated with a protein named as Walker Factor, which was purified from ascitic
fluid obtained from Walker-256 tumour-bearing rats (24 kDa), as described previously by Yano
and colleagues [37], briefly, the ascitic fluid was centrifuged to remove the tumour cells, following
filtration through ultra-centrifugal filter 10,000 MW cut off, and quantified by Western blotting using
proteolysis-induction factor antibody (purified by Cancer Research Laboratory, Aston University,
Birmingham, UK). C2C12 myotubes were incubated with Walker Factor for 24 h at final concentrations
of 25 µg/mL [55]. Leucine/Walker Factor-treated C2C12 myotubes were first exposed to 50 µM leucine
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for 2 h, and then the cells were incubated with fresh DMEM medium leucine supplemented with
Walker Factor at final concentrations of 25 µg/mL. These experiments followed the Control (C2C12C),
Walker Factor (C2C12WF), Leucine supplementation medium (C2C12L) and, Walker Factor and leucine
supplementation medium (C2C12WFL) groups.
4.3. Metabolomics Analysis
Muscle samples and C2C12 myotubes pellet were processed following Le Belle and colleagues’
protocol [56]. Briefly, about 100 mg of muscle tissue fragments or approximately 1 × 106 cells were
added to a cold methanol/chloroform solution (2:1 v/v, in a total of 2.5 mL) and sonicated (VCX 500,
Vibra-Cell, Sonics & Material Inc., CT, USA) for 3 min with a 10-s pause interval between each min.
A cold chloroform/distilled water solution (1:1 v/v, in a total of 2.5 mL) was then added to the samples.
Samples were briefly vortexed (to form an emulsion) and centrifuged at 3.1 × 103 g for 20 min at
4 ◦C. The upper phase (containing methanol, water and polar metabolites) was collected and dried
in a vacuum concentrator (miVac Duo Concentrator, GeneVac, UK). The remaining solid phase was
rehydrated in 0.6 mL of D2O-containing phosphate buffer (0.1 M, pH 7.4) and 0.5 mM of TMSP-d4.
Samples were added to a 5-mm NMR tube for immediate acquisition, using a Varian Inova NMR
spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA) equipped with a triple resonance
probe and operating at a 1H resonance frequency of 500 MHz and constant temperature of 298 K
(25 ◦C). A total of 256 free induction decays were collected with 32-k data points over a spectral width
of 16 ppm. A 1.5-s relaxation delay was incorporated between scans, during which a continual water
presaturation radio frequency field was applied. Spectral phase and baseline corrections, as well as the
identification and quantification of metabolites present in samples, were performed using Chenomx
NMR Suite 7.6 software (Chenomx Inc., Edmonton, AB, Canada).
4.4. Proteomics Analysis
Proteomic analysis was performed in a two-dimensional nano UPLC (2D-RP/RP) in an Acquity
UPLC M-Class System (Waters Corporation, MA, USA), which is connected in line to a Synapt
G2-Si mass spectrometer (Waters Corporation). The mass spectrometer executed Data-Independent
Acquisitions, employing more specifically the Ultra-definition Data-independent Mass Spectrometry
(UDMSE) method [57]. Peptide loads were carried to separation in a nanoACQUITY UPLC HSS T3
Column (1.8 µm, 75µm × 150 mm; Waters Corporation). Peptide elution was achieved using an
acetonitrile gradient from 7% to 40% (v/v) for 95 min at a flow rate of 0.4 µL/min directly into a Synapt
G2-Si. For every measurement, the mass spectrometer was operated in resolution mode with an m/z
resolving power of about 40,000 FWHM, using ion mobility with a cross-section resolving power
at least 40Ω/∆Ω. MS/MS analyses were performed by nano-electrospray ionisation in positive ion
mode nanoESI (+) and a NanoLock Spray (Waters, UK) ionisation source. The lock mass channel
was sampled every 30 sec. Proteins were identified, and quantitative data were processed by using
dedicated algorithms and cross-matched with the UniProt rat proteome database, version 2015/11
(70,225 entries), with the default parameters for ion accounting and quantitation [58]. The databases
used were reversed spontaneously during the database queries and appended to the original database
to assess the false/positive identification rate. For proper spectra processing and database searching
conditions, we used Progenesis QI for a proteomics software package with Apex3D, peptide 3D, and ion
accounting informatics (Waters). This software starts with LC-MS data loading then performs alignment
and peak detection, which creates a list of interested peptide ions (peptides) that are explored within
Peptide Ion Stats by multivariate statistical methods; the final step is protein identity. The following
parameters were considered in identifying peptides: 1. digestion by trypsin allowing one missed
cleavage; 2. methionine oxidation was considered a variable modification and carbamidomethylation
(C), fixed modification; 3. false discovery rate (FDR) less than 1%. These criteria rejected the not satisfied
identifications. For the cellular component, biological processes, and molecular function of quantified
proteins, we used the program DAVID 6.8 [59], Rat Protein Reference Database, and Reactome
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Pathways [60]. Proteins whose variation in abundance was statistically significant, STRING 10 [61]
(considering high-confidence interactions) and KEGG program [62], were used for protein–protein
interaction analyses and evaluations of functional enrichment in the network.
4.5. Oxygen Consumption Rate
The C2C12 myotube cells (1.25 × 106 cells), cultured as described above and treated or not
with Walker Factor and leucine-supplemented medium, for 24 h, were maintained in 6-well
plates or 75-cm2 bottles after differentiation. The oxygen consumption rate (OCR) was monitored
through Oroboros Oxygraph-2K adding sequentially 2 µM oligomycin A, 2 µM Carbonyl cyanide
3-chlorophenylhydrazone and 1 µM antimycin A. The DatLab software package (OROBOROS,
Innsbruck, Austria) was used for data acquisition (2-sec-time intervals) and analysis. The OCR was
expressed as pmol O2 × s−1 × cell.
4.6. Mitochondrial Activity and C2C12 Proliferation
To evaluate mitochondrial activity, C2C12 cells were plated in a 12-well plate until differentiation
into myotubes. The myotubes were then treated as described by in vitro assay (Section 4.2), exposed
to leucine (50 µM, Sigma) and with Walker Factor for 24 h. At the day of the treatment, one plate of
untreated cells was previously read to determine the absorbance at time zero. After 24 h of treatment,
MTT 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (Sigma-Aldrich, MO, USA)
solution was added to the cells at 0.5 mg/mL. After 1.5 h of incubation at 37 ◦C, 100 µL of DMSO was
added to dissolve the formazan crystals. Finally, the absorbance was read using the microplate reader
Cytation 5 (Biotek, Winooski, VT, USA) at λ = 570 nm.
To evaluate cell proliferation, the C2C12 cells were seeded in a 12-well plate and incubated
for 24 h, as described above. Then, using the kit Cell proliferation Assay (Invitrogen, Waltham,
MA USA), and following the manufactures instruction, the treated cells were incubated with EdU
(5-Ethynyl-2′-deoxyuridine) (Invitrogen). After 24 h of treatment, the cells were fixed with 4% PFA
(paraformaldehyde) for 15 min. The coverslips with permeabilised cells, with 0.5% Triton X-100,
were reacted for EdU and stained. Nuclei were labeled with Hoechst 33342, and the slides were
mounted with Mounting medium DAKO (Agilent, Santa Clara, California, CA, USA). The fluorescence
microscope Cytation 5 (Biotek, Winooski, VT, USA) was used (excitation/emission wavelengths
337/447 nm for Hoechst 33342 and 647/794 nm for Alexa Fluor 647) and provided calculation of the
percentage of cell proliferation.
4.7. Electronic Microscopy C2C12 Myotubes
A cell monolayer grown over a glass coverslip was fixed with 2.5% glutaraldehyde and 3 mM
CaCl2 in 0.1 M sodium cacodylate buffer for 5 min at room temperature followed by 1 h of incubation
on ice. After fixation, the samples were washed three times in 0.1 M sodium cacodylate and 3 mM
CaCl2 solution and post-fixed with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer and 0.8%
potassium ferrocyanide for 1 h and en bloc stained in ice-cold 2% uranyl acetate overnight. The cells
were dehydrated in ethanol on ice, ending with four changes of 100% ethanol at room temperature.
The dehydrated cells were infiltrated in Epon resin. After four changes of resin solution, a fifth resin
change was performed, and the dish was immediately placed in a lab oven at 60 ◦C to be polymerised
for 72 h. Ultrathin sections were cut with a Leica Ultracut microtome, stained with 2% uranyl acetate
and Reynold’s lead citrate, and then examined in a LEO 906-Zeiss transmission electron microscope
(at the Electron Microscopy Laboratory of Institute of Biology, Campinas State University) using an
accelerating voltage of 60 kV.
4.8. Western Blot
The gastrocnemius muscles were homogenised in buffer (Tris Base 100 mM, Na4P2O7 10 mM, FNa
100 mM, Na3VO4 1 mM, EDTA 10 mM, PMSF 2 mM, Aprotinin 0.1 mg/mL, Triton X-100 1%, pH 7.4),
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centrifuged, quantified as the total protein analysis [63]. Then, 40 µg muscle homogenate protein
were resolved in SDS acrylamide gels (12%) and transferred to 0.22 µm nitrocellulose membrane
and probed with antibodies against pCREB (Cell Signalling, 1:1000) and OXPHOS Complex I and
IV (Abcam, 1:1000) and corrected by the loading controls vinculin (Cell Signalling, 1:1000), GAPDH
(Cell Signalling, 1:1000) and α-tubulin (SigmaAldrich, 1:10,000). The membranes were then incubated
with secondary antibodies (Cell Signalling, 1:10,000) conjugated with HRP. After chemiluminescence
reaction using ECL reagent (Amersham), the protein bands densitometry analysis was performed using
Image Capture (Amersham) followed the Gel-Pro II software (1.0 version, Silver Spring, Cybernetics,
MD, USA).
4.9. Statistical Analysis
All results of morphometric parameters and metabolomic profile data in skeletal muscle and
myotubes were expressed as the mean ± standard deviation (SD). All analyses were performed by
one-way ANOVA followed by post-hoc Tukey as a multiple comparison test among all experimental
groups and by Student’s t-test for comparison between two experimental groups (e.g., analysis of
the tumour tissue in the W and WL groups). A value of p < 0.05 was considered significant [64].
The statistical analyses were performed using the software Graph Pad Prism 7.0 (Graph-Pad Software,
Inc., San Diego, CA, USA).
The proteomics statistical evaluation of the data was accessed with unique peptides being
normalised using Central Tendency and the absolute deviation of the adjusted median absolute
deviation (MAD), which represents the Max Fold Change, showing the absolute numerical relationship
of how many times the concentration of a protein is statistically higher when comparing one group with
another. The peptides were extrapolated to their corresponding protein through RRollup using the
Grubbs test, with a minimum of three peptides and p < 0.05. The statistical significance of dysregulated
proteins, accessed by the z-score and the p-value associated with a 95% confidence level, were calculated
using robust estimators such as the median and MAD.
5. Conclusions
The mitochondrial catalytic activity is increased in the groups that received a leucine-rich diet
(L and WL). This catalytic activity helps to produce more energy for the muscle tissue throughout
stimuli for pyruvate and acetyl-CoA synthesis. Therefore, the improvement of mitochondrial function
during tumour development by the use of a leucine-rich diet contributes to mitochondrial enzymes
and proteins related to the generation of more energy for the muscle tissue, minimising the effects
of cachexia.
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